Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Non-Current Liabilities (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Other Non-Current Liabilities for 12 consecutive years, with $375.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities rose 8.14% year-over-year to $375.0 million, compared with a TTM value of $375.0 million through Dec 2025, up 8.14%, and an annual FY2025 reading of $367.4 million, up 7.63% over the prior year.
  • Other Non-Current Liabilities was $375.0 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $367.4 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $375.0 million in Q4 2025 and bottomed at $669000.0 in Q2 2023.
  • Average Other Non-Current Liabilities over 4 years is $293.3 million, with a median of $336.0 million recorded in 2024.
  • The sharpest move saw Other Non-Current Liabilities skyrocketed 50128.85% in 2024, then increased 7.21% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $252.8 million in 2022, then rose by 8.24% to $273.7 million in 2023, then increased by 26.7% to $346.8 million in 2024, then grew by 8.14% to $375.0 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for ARWR at $375.0 million in Q4 2025, $367.4 million in Q3 2025, and $360.3 million in Q2 2025.